Evidence map›Paper›PMID 21088244›Full record

ArticleStroke2011

Delayed anti-nogo-a therapy improves function after chronic stroke in adult rats.

Shih-Yen Tsai, Catherine M Papadopoulos, Martin E Schwab, Gwendolyn L Kartje

Open access · bronzeAbstract read
In one paragraph

Article in Stroke, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 106 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Anti-NOGO Antibody Neuroprotection in a Rat Model of NAION.Translational vision science & technology · 2021
    Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Experimental pediatric stroke shows age-specific recovery of cognition and role of hippocampal Nogo-A receptor signaling.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2020
    Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Shih-Yen TsaiNeurology and Research Service, Edward Hines Jr VA Hospital, Hines, IL 60141, USA. shih-yen.tsai@va.gov
Catherine M Papadopoulos
Martin E Schwab
Gwendolyn L Kartje
University of Zurich · CH

Funding

Neuron Plasticity and Recovery of Function After StrokeR01NS040960 · NINDS · LOYOLA UNIVERSITY CHICAGO · PI KARTJE, GWENDOLYN LOUISE · 2001 to 2010
$2.2M
Neuronal Plasticity and Recovery of Function After StrokeR56NS040960 · NINDS · LOYOLA UNIVERSITY CHICAGO · PI KARTJE, GWENDOLYN LOUISE · 2011 to 2011
$312k
Immunotherapy to Improve Functional Outcomes after Chronic Stoke in the AgedI01RX000828 · VA · EDWARD HINES JR VA HOSPITAL · PI KARTJE, GWENDOLYN LOUISE · 2012 to 2015
–
NINDS NIH HHS R01 NS040960NINDS NIH HHS R56 NS040960PHS HHS 40960RRD VA I01 RX000828
6 · The paper itself

Abstract

background and purposewe have shown that anti-Nogo-A immunotherapy to neutralize the neurite growth inhibitory protein Nogo-A results in functional improvement and enhanced plasticity after ischemic stroke in the adult rat. The present study investigated whether functional improvement and neuronal plasticity can be induced by this immunotherapy when administered to the chronic stroke-impaired rat.

methodsadult rats were trained to perform the skilled forelimb reaching test, followed by permanent middle cerebral artery occlusion to impair the preferred forelimb. Nine weeks after stroke, animals showing a profound deficit were randomly distributed to 3 groups: no treatment, control antibody, or anti-Nogo-A antibody (11C7). Animals were tested weekly after stroke surgery and daily after antibody treatment until the end of the study. Biotin dextran amine tracing was injected into the nonlesioned forelimb motor cortex at the end of behavioral testing to determine axonal plasticity.

resultsall rats showed similar forelimb impairment before treatment. Animals treated with anti-Nogo-A immunotherapy started to show improvement 3 weeks after treatment. Such improvement became significantly better than stroke-only control and control Ab-treated animals, and persisted to the end of the study. Biotin dextran amine-labeled axonal fiber analysis also showed significant enhanced corticorubral axonal sprouting from the contralesional forelimb motor cortex to the deafferented red nucleus in the anti-Nogo-A immunotherapy rats.

conclusionsthese results indicate that improvement of chronic neurological deficits and enhancement of neuronal plasticity can be induced in the adult rat with anti-Nogo-A immunotherapy, and that this therapy may be used to restore function even when administered long after ischemic brain damage has occurred.

Indexed as

ImmunotherapyAnimalsAntibodies, MonoclonalAxonsChronic DiseaseMaleMyelin ProteinsNeuronal PlasticityNogo ProteinsRatsRats, Long-EvansRecovery of FunctionStrokeTime FactorsAntibodies, MonoclonalMyelin ProteinsNogo ProteinsRtn4 protein, rat

Identifiers

PMID21088244
PMCPMC3806087
OpenAlexW2134396069

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.